hs-CRP Biomarker in Breast Cancer

Apr 11, 2012 by

Regular monitoring of hs-CRP holds promise as a biomarker for identifying women with early-stage breast cancer at low risk for asymptomatic trastuzumab-induced cardiotoxicity. Easily obtainable biomarker with rapid results for evaluating cardiotoxicity related to trastuzumab therapy.

Related Posts

Tags

Share This

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>